ClinicalTrials.gg
TerminatedNCT01534351Updated Aug 29, 2018Results posted

Comparison of Finasteride and Tamsulosin for Treatment of Benign Prostatic Hyperplasia (BPH) (MK-0906A-149 AM2)

A Phase 3 interventional study of Finasteride and Tamsulosin in Benign Prostatic Hyperplasia, sponsored by Merck Sharp & Dohme LLC. Terminated. Open to male participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2018-08-29.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

Why this study was terminated
Business Reasons

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1
Allocation
Randomized
Ages
50 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing finasteride in Prostatic Hyperplasia — 1 open to participants now, 2 under way, 1 of them phase 3. Finasteride · Prostatic Hyperplasia.

Enrollment
9th of 10
1 · median 75
Started
2013
the only one that year
Phase 3
5 of 10
1 open now
Registered
6th of 10
by date
Lead sponsor
1 of 10
Merck Sharp & Dohme LLC

Among the 10 studies testing finasteride in Prostatic Hyperplasia, this one is the 9th largest by enrollment, is the only one that started in 2013, is one of 5 in phase 3, and was the 6th registered.

Prostatic Hyperplasia

828 studies on the registry are indexed under Prostatic Hyperplasia; 179 are open to participants now.

Browse Prostatic Hyperplasia studies →

Open to participants now

1 of the 10 studies testing finasteride in Prostatic Hyperplasia is open now. Recruiting first, the newest first:

About finasteride

Finasteride: first FDA approval 1992 (PROSCAR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 102 Prostatic Hyperplasia studies recruiting now, 70 (69%) set no upper age limit and 4 (4%) stop at 75 or younger; 7 take children under 18; 7 take healthy volunteers.

This study: 50 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing finasteride in Prostatic Hyperplasia, or all of them as a file.
02

Study summary

This study is designed to compare safety and efficacy of monotherapy finasteride to combination therapy (finasteride and tamsulosin) in Asian men with benign prostatic hyperplasia (BPH) who are at least 50 years of age or older. The primary hypotheses are that concomitantly-dosed finasteride 5 mg and tamsulosin 0.2 mg will be superior with respect to BPH symptoms compared to monotherapy with finasteride 5 mg as measured by change from baseline on the International Prostate Symptoms Score (IPSS) and will be superior with respect to prostate volume reduction compared to montherapy with tamsulosin 0.2 mg as measured by percent change from baseline in prostate volume.

03

Conditions studied

  • Benign Prostatic Hyperplasia

Browse trials for

04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Possess a clinical diagnosis of BPH.
  • Able to read, understand, and complete the study questionnaire.

Exclusion criteria

Exclusion Criteria:

  • History or recurrent evidence of any condition, therapy, lab abnormality or other circumstance that might confound the results of the study, or interfere with participation for the full duration of the study.
  • History of ≤ 5 years prior to signing , except for adequately treated basal cell or squamous cell skin cancer, including prostate cancer of any duration, evidence or suspicion of prostate cancer on a previous .
  • History of prostatic surgery or other invasive procedures to treat BPH or history of bladder neck obstruction, bladder cancer, and/or pelvic irradiation, urinary incontinence, recurrent urinary tract infection, urethral stricture, or bacterial prostatitis.
  • History of acute urinary retention (ie, inability to fully empty bladder).
  • Had invasive urinary bladder procedures (ie, cystoscopy) within 7 days prior to screening.
  • Had phytotherapy within 2 weeks of screening and may need phytotherapy during the study.
  • History of low blood pressure (orthostatic hypotension, hypotension [supine blood pressure less than 90/70 mm Hg]), unstable angina, or a cardiovascular or cerebral vascular event (ie, [TIA], stroke) within the previous 3 months prior to enrollment, OR a history of dizziness, vertigo or any other typical signs and symptoms of low blood pressure.
  • Recent history (ie, within the past year) or active addiction, abuse, misuse of and/or dependence on drugs and/or alcohol.
  • Use of herbal therapies that may impact the study (eg, Saw Palmetto) within 2 weeks of screening and/or is predicted to need herbal therapies during the study. Individuals currently taking herbal therapies may be eligible for study if willing to complete a 2-week .
  • Use of finasteride or a drug with a similar action during the 12 months prior to study screening. Individuals treated for short periods with 5-alpha reductase inhibitors (5ARIs) or drugs with antiandrogenic properties within 12 months of screening may be eligible for study.
  • Use of a non-approved () drug within the last 4 weeks prior to enrollment, or current participation in another clinical study.
  • Allergic or intolerant to finasteride and/or tamsulosin.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1 participant (actual)

Study arms

  • Experimental
    Finasteride

    Finasteride 5 mg taken orally once daily and tamsulosin-matching placebo taken orally once daily for 12 months. The tamsulosin-matching placebo will be taken approximately one half hour following the same meal each day. Medications may be taken separately or together.

    Drug: Finasteride · Drug: Tamsulosin-matching placebo

  • Active comparator
    Tamsulosin

    Tamsulosin 0.2 mg taken orally once daily and finasteride-matching placebo taken orally once daily for 12 months. The tamsulosin will be taken approximately one half hour following the same meal each day. Medications may be taken separately or together.

    Drug: Tamsulosin · Drug: Finasteride-matching placebo

  • Experimental
    Finasteride and Tamsulosin

    Finasteride 5 mg orally once daily and tamsulosin 0.2 mg orally once daily for 12 months, taken concomitantly. The tamsulosin will be taken approximately one half hour following the same meal each day. Medications may be taken separately or together.

    Drug: Finasteride · Drug: Tamsulosin

Interventions

  • Finasteride 5 mg oral tablet taken once daily.

    Also known as: Proscar®

  • Tamsulosin 0.2 mg oral capsule taken once daily.

    Also known as: Flomax®

  • DrugFinasteride-matching placebo

    Matching placebo to finasteride 5 mg oral tablet taken once daily.

  • DrugTamsulosin-matching placebo

    Matching placebo to tamsulosin 0.2 mg oral capsule taken once daily.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in International Prostate Symptom Score (IPSS)

    The IPSS is a self-administered questionnaire used to measure the severity of lower urinary tract symptoms among men suspected of having symptomatic Benign Prostatic Hyperplasia (BPH). The IPSS consists of 8 questions (7 urinary symptom questions + 1 quality of life question). The 7 symptom questions inquire about frequency, nocturia, weak urinary stream, hesitancy, intermittence, incomplete emptying and urgency. Each of the 7 questions has an ordered categorical response frame scored from 0 (not at all) to 5 (almost all the time). The total score is the sum of the 7 items and therefore has a range of 0 to 35. Higher scores indicate higher symptom severity. The quality of life question is a single global question rated on a scale of 0 (delighted) to 6 (terrible) asking the participant to rate how they feel about their current urinary symptom status. The IPSS-QoL question is not used in the calculation of the total symptom score.

    Time frame: Baseline and Month 12

  2. Percent Change From Baseline in Prostate Volume

    Prostate volume was assessed by trans-rectal ultrasound (TRUS).

    Time frame: Baseline and Month 12

  3. Number of Participants Who Experienced an Adverse Event

    An adverse event is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the Sponsor's product, whether or not considered related to the use of the product.

    Time frame: Up to 54 weeks

  4. Number of Participants Who Discontinued Treatment Due to an Adverse Event

    An adverse event is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the Sponsor's product, whether or not considered related to the use of the product.

    Time frame: Up to 52 weeks

07

Results

Posted Dec 3, 2015
Limitations and caveats
The trial was terminated for business reasons.

Participant flow

Participant flow — Overall Study
MilestoneFinasterideTamsulosinFinasteride and Tamsulosin
Started100
Completed000
Not completed100
Withdrew: Study terminated early100

Outcome measures

PrimaryChange From Baseline in International Prostate Symptom Score (IPSS)

The IPSS is a self-administered questionnaire used to measure the severity of lower urinary tract symptoms among men suspected of having symptomatic Benign Prostatic Hyperplasia (BPH). The IPSS consists of 8 questions (7 urinary symptom questions + 1 quality of life question). The 7 symptom questions inquire about frequency, nocturia, weak urinary stream, hesitancy, intermittence, incomplete emptying and urgency. Each of the 7 questions has an ordered categorical response frame scored from 0 (not at all) to 5 (almost all the time). The total score is the sum of the 7 items and therefore has a range of 0 to 35. Higher scores indicate higher symptom severity. The quality of life question is a single global question rated on a scale of 0 (delighted) to 6 (terrible) asking the participant to rate how they feel about their current urinary symptom status. The IPSS-QoL question is not used in the calculation of the total symptom score.

Time frame:
Baseline and Month 12

No measurements were reported for this outcome.

PrimaryPercent Change From Baseline in Prostate Volume

Prostate volume was assessed by trans-rectal ultrasound (TRUS).

Time frame:
Baseline and Month 12

No measurements were reported for this outcome.

PrimaryNumber of Participants Who Experienced an Adverse Event

An adverse event is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the Sponsor's product, whether or not considered related to the use of the product.

Time frame:
Up to 54 weeks
Reported as:
Number · Participants
Number of Participants Who Experienced an Adverse Event
ParticipantsFinasterideTamsulosinFinasteride and Tamsulosin
Number of Participants Who Experienced an Adverse Event0——
PrimaryNumber of Participants Who Discontinued Treatment Due to an Adverse Event

An adverse event is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the Sponsor's product, whether or not considered related to the use of the product.

Time frame:
Up to 52 weeks
Reported as:
Number · Participants
Number of Participants Who Discontinued Treatment Due to an Adverse Event
ParticipantsFinasterideTamsulosinFinasteride and Tamsulosin
Number of Participants Who Discontinued Treatment Due to an Adverse Event0——

Adverse events

Collected over Up to 54 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Finasteride—0/1 (0%)0/1 (0%)
Tamsulosin———
Finasteride and Tamsulosin———

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)FinasterideTamsulosinFinasteride and TamsulosinTotal
<=18 years0——0
Between 18 and 65 years1——1
>=65 years0——0
Sex: Female, Male
Sex: Female, Male(Participants)FinasterideTamsulosinFinasteride and TamsulosinTotal
Female0——0
Male1——1
08

Study locations

No study locations are listed for this record.

09

References and documents

Individual participant data

Plan to share: Yes — https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2013 to primary completion in Nov 2013, 3 months.

Results were first posted in Dec 2015, 2 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 13, 2012
First posted
Feb 16, 2012
StartActual
Aug 1, 2013
Primary completionActual
Nov 18, 2013
CompletionActual
Nov 18, 2013
Results first posted
Dec 3, 2015
Last update
Aug 29, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 29, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01534351
Responsible party
Sponsor
First posted
Feb 16, 2012
Start date
Aug 1, 2013
Primary completion
Nov 18, 2013
Completion
Nov 18, 2013
Results posted
Dec 3, 2015
Last update
Aug 29, 2018

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Finasteride · Tamsulosin

Start the discussion